Dr. Garfall on Impact of CAR T-Cell Therapy in Hematologic Malignancies

Alfred L. Garfall, MD, MS
Published: Wednesday, Mar 22, 2017


Alfred L. Garfall, MD, MS, assistant professor of Medicine, the Hospital of the University of Pennsylvania, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.

The use of CAR T-cell therapies for patients with hematologic malignancies has become a very remarkable and translational medicine story that has played out over the last 20 years, Garfall explains. This type of treatment has also come into clinical application use in the last 5 years with pilot and multicenter studies that are targeting CD19 with CAR T cells in patients with various B-cell malignancies, he adds. Another target includes BCMA in multiple myeloma. Soon, the community could see the first FDA approval of CAR T-cell therapy.

An ongoing conversation among oncologists is discussing the various data available for CAR T-cell therapies explored in chronic lymphocytic leukemia, acute lymphoblastic leukemia, and non-Hodgkin lymphoma and comparing the response rates and safety profiles, he adds.
SELECTED
LANGUAGE

Alfred L. Garfall, MD, MS, assistant professor of Medicine, the Hospital of the University of Pennsylvania, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.

The use of CAR T-cell therapies for patients with hematologic malignancies has become a very remarkable and translational medicine story that has played out over the last 20 years, Garfall explains. This type of treatment has also come into clinical application use in the last 5 years with pilot and multicenter studies that are targeting CD19 with CAR T cells in patients with various B-cell malignancies, he adds. Another target includes BCMA in multiple myeloma. Soon, the community could see the first FDA approval of CAR T-cell therapy.

An ongoing conversation among oncologists is discussing the various data available for CAR T-cell therapies explored in chronic lymphocytic leukemia, acute lymphoblastic leukemia, and non-Hodgkin lymphoma and comparing the response rates and safety profiles, he adds.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x